

Satoreotide

| | |
|----------------------|---|
| Cat. No.: | HY-P10137 |
| CAS No.: | 1801415-23-5 |
| Molecular Formula: | C ₅₈ H ₇₂ ClN ₁₅ O ₁₄ S ₂ |
| Molecular Weight: | 1302.87 |
| Sequence: | {p-Cl-Phe}-cyclo({d-Cys}-F-{d-4-amino-Phe(carbamoyl)}-KTC)-{d-Tyr}-NH ₂ |
| Sequence Shortening: | FCFFKTCY |
| Target: | Somatostatin Receptor |
| Pathway: | GPCR/G Protein; Neuronal Signaling |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaging ^[1] . |
| IC ₅₀ & Target | SSTR2 |

REFERENCES

[1]. Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA